Lesson learned from the COMPASS and VOYAGER PAD trials: dual pathway inhibition as a new antithrombotic paradigm?

Eur J Prev Cardiol. 2022 May 5;29(5):e178-e180. doi: 10.1093/eurjpc/zwab137.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Aspirin / adverse effects
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Peripheral Arterial Disease* / drug therapy
  • Platelet Aggregation Inhibitors / adverse effects
  • Rivaroxaban* / adverse effects

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • Rivaroxaban
  • Aspirin